Dmitry Balyasny’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $60.3M | Sell |
1,054,613
-308,139
| -23% | -$16.9M | 0.08% | 312 |
|
|
2026
Q1 | $77M | Buy |
+1,362,752
| New | +$79.5M | 0.1% | 227 |
|
|
2025
Q4 | – | Sell |
-252,825
| Closed | -$13.8M | – | 3103 |
|
|
2025
Q3 | $13.7M | Sell |
252,825
-187,875
| -43% | -$10.7M | 0.02% | 894 |
|
|
2025
Q2 | $24.2M | Buy |
440,700
+432,953
| +5,589% | +$25.5M | 0.04% | 599 |
|
|
2025
Q1 | $548K | Sell |
7,747
-329,356
| -98% | -$22.2M | ﹤0.01% | 2243 |
|
|
2024
Q4 | $22.2M | Sell |
337,103
-573,513
| -63% | -$38.4M | 0.03% | 614 |
|
|
2024
Q3 | $64M | Sell |
910,616
-112,876
| -11% | -$9.44M | 0.1% | 230 |
|
|
2024
Q2 | $84.3M | Buy |
1,023,492
+786,547
| +332% | +$65.5M | 0.15% | 162 |
|
|
2024
Q1 | $20.7M | Sell |
236,945
-187,624
| -44% | -$16.8M | 0.04% | 606 |
|
|
2023
Q4 | $40.9M | Sell |
424,569
-485,827
| -53% | -$43M | 0.08% | 321 |
|
|
2023
Q3 | $80.6M | Buy |
910,396
+793,863
| +681% | +$70.6M | 0.16% | 151 |
|
|
2023
Q2 | $10.1M | Sell |
116,533
-189,591
| -62% | -$17.8M | 0.02% | 772 |
|
|
2023
Q1 | $29.8M | Buy |
306,124
+98,520
| +47% | +$10.2M | 0.07% | 382 |
|
|
2022
Q4 | $21.5M | Sell |
207,604
-578,184
| -74% | -$54.3M | 0.06% | 463 |
|
|
2022
Q3 | $66.6M | Buy |
785,788
+221,090
| +39% | +$19.7M | 0.2% | 102 |
|
|
2022
Q2 | $46.8M | Buy |
564,698
+545,848
| +2,896% | +$43.5M | 0.15% | 165 |
|
|
2022
Q1 | $1.45M | Buy |
+18,850
| New | +$1.58M | ﹤0.01% | 1521 |
|
|
2021
Q2 | – | Sell |
-19,657
| Closed | -$1.48M | – | 1975 |
|
|
2021
Q1 | $1.48M | Sell |
19,657
-143,752
| -88% | -$11.7M | 0.01% | 1132 |
|
|
2020
Q4 | $14.3M | Buy |
163,409
+126,828
| +347% | +$10.1M | 0.08% | 346 |
|
|
2020
Q3 | $2.78M | Sell |
36,581
-70,245
| -66% | -$7.11M | 0.02% | 754 |
|
|
2020
Q2 | $13.2M | Sell |
106,826
-259,466
| -71% | -$25.8M | 0.11% | 273 |
|
|
2020
Q1 | $31M | Sell |
366,292
-258,125
| -41% | -$22.2M | 0.37% | 57 |
|
|
2019
Q4 | $52.8M | Buy |
624,417
+477,401
| +325% | +$36.1M | 0.31% | 74 |
|
|
2019
Q3 | $9.91M | Sell |
147,016
-260,750
| -64% | -$20.1M | 0.07% | 398 |
|
|
2019
Q2 | $34.9M | Buy |
407,766
+393,462
| +2,751% | +$33.7M | 0.22% | 115 |
|
|
2019
Q1 | $1.27M | Sell |
14,304
-218,287
| -94% | -$20.2M | 0.01% | 950 |
|
|
2018
Q4 | $19.8M | Sell |
232,591
-290,220
| -56% | -$27.6M | 0.14% | 203 |
|
|
2018
Q3 | $50.7M | Buy |
522,811
+106,041
| +25% | +$10.6M | 0.23% | 105 |
|
|
2018
Q2 | $39.3M | Sell |
416,770
-621,529
| -60% | -$54.4M | 0.18% | 145 |
|
|
2018
Q1 | $84.2M | Sell |
1,038,299
-713,092
| -41% | -$61.2M | 0.35% | 51 |
|
|
2017
Q4 | $156M | Buy |
1,751,391
+689,779
| +65% | +$60M | 0.49% | 27 |
|
|
2017
Q3 | $98.8M | Buy |
1,061,612
+806,372
| +316% | +$71.3M | 0.39% | 52 |
|
|
2017
Q2 | $23.2M | Sell |
255,240
-340,174
| -57% | -$30.9M | 0.1% | 283 |
|
|
2017
Q1 | $52.3M | Buy |
595,414
+144,944
| +32% | +$12.9M | 0.24% | 102 |
|
|
2016
Q4 | $37.3M | Sell |
450,470
-96,318
| -18% | -$8.28M | 0.2% | 131 |
|
|
2016
Q3 | $50.6M | Buy |
546,788
+179,987
| +49% | +$16.9M | 0.29% | 109 |
|
|
2016
Q2 | $28.5M | Buy |
366,801
+71,079
| +24% | +$6.04M | 0.18% | 148 |
|
|
2016
Q1 | $24.4M | Sell |
295,722
-179,132
| -38% | -$14.6M | 0.14% | 208 |
|
|
2015
Q4 | $49.7M | Buy |
474,854
+226,225
| +91% | +$23.6M | 0.35% | 79 |
|
|
2015
Q3 | $26.2M | Sell |
248,629
-289,129
| -54% | -$38.6M | 0.19% | 139 |
|
|
2015
Q2 | $73.6M | Buy |
+537,758
| New | +$66.6M | 0.45% | 44 |
|
|
2014
Q3 | – | Sell |
-114,852
| Closed | -$7.14M | – | 708 |
|
|
2014
Q2 | $7.14M | Buy |
+114,852
| New | +$6.94M | 0.08% | 305 |
|
Other funds holding BMRN
VPC
Dmitry Balyasny's BMRN Position: Q2 2026 in Review
Dmitry Balyasny reduced its BioMarin Pharmaceuticals (BMRN) stake by 23% in Q2 2026, selling an estimated $16.9M and leaving 1,054,613 shares worth $60.3M. The position accounts for 0.08% of the portfolio, ranked #312.
Dmitry Balyasny first reported a position in BMRN in Q2 2014 and has held it in 42 quarters since. The position peaked at $156M in Q4 2017. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- Dmitry Balyasny held 1,054,613 shares of BioMarin Pharmaceuticals worth $60.3M as of Q2 2026.
- Dmitry Balyasny sold 308,139 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $16.9M.
- BioMarin Pharmaceuticals made up 0.08% of Dmitry Balyasny's portfolio in Q2 2026, its #312 holding.
- Dmitry Balyasny first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 42 quarters since.
- Dmitry Balyasny's BioMarin Pharmaceuticals position peaked at $156M in Q4 2017.
- 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.